Gold Micro Shunt Plus (GMS+) implantation is not an effective method for controlling IOP in glaucoma patients, according to a recent study in the journal BMC Ophthalmology.
Gold Micro Shunt Plus (GMS+) implantation is not an effective method for controlling IOP in glaucoma patients, according to a recent study in the journal BMC Ophthalmology.
Dr Arno Hueber et al., Department of Ophthalmology, University of Cologne, Germany, conducted a retrospective study on 31 eyes of 31 patients with severe glaucoma and uncontrolled IOP. Each patient underwent GMS+ implantation by means of a full-thickness scleral flap. The main outcome measures were surgical failure or success, determined by intraocular pressure and adverse effects.
Of the eyes included in the study, 30 met one of the failure criteria. Additional surgery was performed due to elevated IOP in 24 eyes and adverse effects in 2 eyes.
The remaining four eyes presented with an IOP reduction of less than 20% with comparable medication. The team explanted six GMS+’s because of IOP elevation in 2 eyes, rubeosis in 2 eyes and low-grade inflammation in 2 eyes.
GMS+ implantation is not effective for the control of IOP in glaucoma patients and the reason for the appearance of low grade inflammation and rubeosis iridis in 4 eyes remains unknown.
To read the abstract please click here.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.